A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide
1996

Ovarian Cancer Treatment with Intensive Chemotherapy

Sample size: 14 publication Evidence: moderate

Author Information

Author(s): A Weaver, E Wrigley, A Watson, J Chang, CD Collins, B Jenkins, C Gill, R Pettengell, TM Dexter, NG Testa, D Crowther

Primary Institution: Christie Hospital, Manchester

Hypothesis

Can dose-intensive chemotherapy supported by peripheral blood progenitor cells improve outcomes in ovarian cancer patients?

Conclusion

The study found that dose-intensive chemotherapy can be safely administered with low toxicity, achieving a 70% overall response rate in ovarian cancer patients.

Supporting Evidence

  • Five patients achieved complete remission, and five achieved partial remission, resulting in a 70% overall response rate.
  • Patients treated with the 3-week regimen tolerated the treatment well, with 83% receiving the planned dose intensity.
  • Thrombocytopenia was the main reason for treatment delays in the 2-week regimen.

Takeaway

Doctors tested a stronger chemotherapy for ovarian cancer and found it worked well for most patients without making them too sick.

Methodology

Patients received filgrastim to mobilize progenitor cells, followed by chemotherapy with cyclophosphamide and carboplatin, with apheresis to collect progenitor cells.

Potential Biases

Potential bias due to the small number of patients and the lack of a control group.

Limitations

The small sample size and the fact that not all patients completed the treatment as planned due to side effects.

Participant Demographics

Patients aged 16 to 65 with histologically proven epithelial ovarian cancer, FIGO stage Ic-IV.

Statistical Information

P-Value

0.03

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication